ABSTRACT
Skin grafting is a simple method for reconstruction of a large defect on the foot. Although skin grafting on the foot sometimes fails, it is not clear what factors influence the success rate of skin grafting. We analyzed data for 71 patients with skin cancer of the foot who underwent reconstruction of defects with skin grafting. The factors we evaluated were success rate of skin grafting, weight-bearing or non-weight-bearing area, immediate or delayed reconstruction, and whether a tie-over bolster was used or not. The success rates were higher in patients with lesions in non-weight-bearing areas than in patients with lesions in weight-bearing areas and in patients who underwent delayed reconstruction than in patients who received immediate reconstruction. On the other hand, the use of a tie-over bolster did not improve the success rate. In conclusion, delayed reconstruction is desirable if the lesion is located in a weight-bearing area.
Subject(s)
Melanoma/surgery , Plastic Surgery Procedures/adverse effects , Skin Neoplasms/surgery , Skin Transplantation/adverse effects , Surgical Flaps/adverse effects , Adult , Aged , Aged, 80 and over , Female , Foot/surgery , Humans , Male , Middle Aged , Plastic Surgery Procedures/methods , Retrospective Studies , Skin Transplantation/methods , Time Factors , Treatment Outcome , Weight-BearingSubject(s)
Antineoplastic Agents, Alkylating/adverse effects , Catheterization, Central Venous/adverse effects , Extravasation of Diagnostic and Therapeutic Materials/diagnosis , Extravasation of Diagnostic and Therapeutic Materials/surgery , Trabectedin/adverse effects , Antineoplastic Agents, Alkylating/administration & dosage , Biopsy , Diagnosis, Differential , Humans , Male , Middle Aged , Skin Transplantation , Trabectedin/administration & dosage , Wound Closure TechniquesSubject(s)
Adenocarcinoma/genetics , DNA-Binding Proteins/genetics , Nuclear Proteins/genetics , Sweat Gland Neoplasms/genetics , Transcription Factors/genetics , Translocation, Genetic/genetics , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Axilla , Biopsy , Diagnosis, Differential , Female , Humans , Middle Aged , Sweat Gland Neoplasms/pathology , Sweat Gland Neoplasms/surgery , Trans-ActivatorsABSTRACT
Knowledge of the prevalence of symptoms in patients with incurable cancer in the terminal stage is important for clinicians. However, there has been no report on the prevalence of symptoms in patients with incurable skin cancer. We analyzed the prevalence of symptoms in 224 patients who died due to skin cancer in our center. These data were obtained from medical records compiled by a miscellaneous population of medical staff retrospectively. We evaluated the symptoms at 3 months, 1 month, 2 weeks, 1 week and 3 days before the patients died. Data for symptoms included Eastern Cooperative Oncology Group performance status and the presence or absence of the following 13 symptoms: (i) bleeding or exudate; (ii) pain or necessity for an analgesic; (iii) fatigue; (iv) anorexia; (v) nausea; (vi) dyspnea or need for oxygen administration; (vii) bloating; (viii) insomnia; (ix) delirium; (x) drowsiness; (xi) anemia; (xii) spasm; and (xiii) paralysis. The average performance status gradually progressed. Pain and anorexia were the most common symptoms in patients with advanced skin cancer. Dyspnea, anemia and drowsiness also tended to be frequent as death approached despite the fact that the frequencies of these symptoms were not high 3 months before death. We considered that frequencies of prevalence of pain and dyspnea were due to bone and lung metastases. Bleeding or exudate from lesions is a characteristic symptom in patients with skin cancer. Our results regarding the prevalence of symptoms in patients with advanced skin cancer will be helpful for medical professionals to assess patients' conditions and to plan treatment.
Subject(s)
Skin Neoplasms/complications , Terminally Ill/statistics & numerical data , Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Japan/epidemiology , Male , Middle Aged , Prevalence , Skin Neoplasms/epidemiology , Young AdultABSTRACT
Cutaneous adverse events are relatively common in patients being treated with molecular-targeted drugs. Paronychia is one of the cutaneous adverse events that influences the patient's quality of life because of pain, and it often affects anticancer treatments in severe cases. However, there are few effective treatments, especially for severe paronychia. Here, we present our experiences of treatment for paronychia due to oncology pharmacotherapy. Although we treated paronychia with various methods, only corticosteroid ointment and phenol chemical matricectomy significantly improved the paronychia. Dermatologists must perform appropriate and effective treatments for paronychia in order to enable patients to continue anticancer drug treatment without impairing their quality of life.
